CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024

Rhea-AI Summary

CVRx, Inc. (NASDAQ: CVRX) will release its first quarter 2024 financial and operating results on April 30th, 2024, followed by a conference call to discuss the results. The company focuses on developing, manufacturing, and commercializing Barostim™, an innovative neuromodulation device for cardiovascular diseases.

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30^th, 2024. The Company will host a conference call to review its results at 5:00pm Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:

Laura O’Neill
Finn Partners
212-867-1762
laura.oneill@finnpartners.com

FAQ

When will CVRx release its first quarter 2024 financial and operating results?

CVRx will release its first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024.

What is the focus of CVRx as a company?

CVRx is a commercial-stage medical device company focused on developing, manufacturing, and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases.

Where can investors listen to the conference call discussing CVRx's first quarter 2024 results?

Investors can listen to the conference call discussing CVRx's first quarter 2024 results on the investor relations page of the Company’s website at ir.cvrx.com or by dialing 1-877-704-4453 for U.S. callers or 1-201-389-0920 for international callers.